deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03770455

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

PDL-1 Inhibition With Avelumab and Concurrent Second-generation ADT in African Americans With Castrate-resistant Metastatic Prostate Cancer

Sponsor: EMD Serono

Conditions Metastatic Castration-resistant Prostate Cancer
Interventions 2nd generation ADT (abiraterone or enzalutamide) Avelumab
Updated 12 times since 2019 Last updated: Jun 26, 2024 Started: Jan 25, 2019 Primary completion: Dec 17, 2020 Completion: Jan 7, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Early signs of progression and learned experience that the assumed time period between psa progression and radiographic progression was shorter than expected

Other terminated trials from EMD Serono

See all terminations from EMD Serono

Other Metastatic Castration-resistant Prostate Cancer trials with similar outcome

Browse all Metastatic Castration-resistant Prostate Cancer trials

A PHASE2 clinical study on Metastatic Castration-resistant Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by EMD Serono and has accumulated 12 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2019 – ~Jun 2020 · 16 months · monthly snapshotRecruiting~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshotActive Not Recruiting~Feb 2022 – ~Jun 2022 · 4 months · monthly snapshotTerminated~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotTerminated~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Jun 2022 — Dec 2022 [monthly]

    Terminated PHASE2

  2. Feb 2022 — Jun 2022 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Jan 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  6. Feb 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jan 2019 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • EMD Serono
  • Jodi Layton, MD
Data source: Tulane University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations